Anika Therapeutics Inc (NAS:ANIK)
$ 16.9601 0.6601 (4.05%) Market Cap: 248.39 Mil Enterprise Value: 201.25 Mil PE Ratio: 0 PB Ratio: 1.39 GF Score: 80/100

Q3 2020 Anika Therapeutics Inc Earnings Call Transcript

Nov 04, 2020 / 10:00PM GMT
Release Date Price: $36.77 (+4.94%)
Operator

Good evening, ladies and gentlemen, and welcome to Anika's Third Quarter 2020 Earnings Conference Call. As a reminder, all participants are in listen-only mode and the conference is being recorded. (Operator Instructions).

I will now turn the conference over to Kristen Galfetti, Executive Director of Investor Relations. Please proceed.

Kristen Galfetti
Anika Therapeutics, Inc. - Executive Director of IR

Thank you, Galeen. Good evening, everyone, and thank you for joining us. With me on the call today is Dr. Cheryl Blanchard, President and Chief Executive Officer; and Mike Levitz, Executive Vice President, Chief Financial Officer and Treasurer of Anika. During today's call, Cheryl and Mike will review Anika's third quarter 2020 financial results and key business highlights, which were summarized in our earnings release issued today. A copy of the earnings release is available on the Investor Relations section of our website at anika.com. In addition, a slide presentation is posted on our website in the Investor Relations section under the Events and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot